Standout Papers

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy 2006 2026 2012 2019 2.2k
  1. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (2006)
    Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine
  2. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009)
    Philip Home, Stuart Pocock et al. The Lancet
  3. Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis (2007)
    Philip Home, Stuart Pocock et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 6 from Science/Nature 134 standout
Sub-graph 1 of 16

Citing Papers

The changing landscape of atherosclerosis
2021 StandoutNature
Pharmacological treatment of hyperglycemia in type 2 diabetes
2021 Standout
50 intermediate papers

Works of Nigel C. Jones being referenced

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
A Diabetes Outcome Progression Trial (ADOPT)
2002
and 6 more

Author Peers

Author Last Decade Papers Cites
Nigel C. Jones 2046 4016 1521 3599 170 9.8k
Jürgen Schnermann 911 5177 549 1748 228 13.4k
Roland N. Auer 3086 2194 527 1064 144 8.4k
Lucio Annunziato 3487 4931 444 1205 281 10.0k
Patricia D. Hurn 2509 4493 353 2784 180 15.9k
Susan J. Vannucci 1826 3563 372 1145 120 10.8k
Yadong Huang 2692 5175 1154 1693 142 13.6k
Elizabeth R. Seaquist 817 1510 369 4570 151 9.7k
Anders A. F. Sima 2770 3690 544 2675 254 15.2k
Hanno Pijl 651 1833 373 2813 276 9.8k
John A. Peters 5093 6098 457 820 105 12.6k

All Works

Loading papers...

Rankless by CCL
2026